Post by AstraZeneca

In blood cancer, assessing treatment response can be complex, even when there are no visible signs of disease. Minimal residual disease (MRD) testing is becoming an important area of progress and as technology continues to advance, it has the potential to inform prognosis, guide treatment decisions and accelerate drug development. Find out more about how we are working across our haematology portfolio and with partners to advance the science of MRD: https://lnkd.in/e6PKcjAr